Comparative in vitro study of SQ26,776.

Area of Science:

• Microbiology
• Pharmacology
• Infectious Diseases

Background:

• The emergence of antibiotic resistance necessitates the development of new antimicrobial agents.
• Gram-negative bacilli are a significant cause of hospital-acquired infections, often exhibiting resistance to existing therapies.

Purpose of the Study:

• To evaluate the in vitro activity of a novel monocyclic beta-lactam antibiotic, SQ26,776.
• To compare the efficacy of SQ26,776 against clinical isolates with established antibiotics.

Main Methods:

• In vitro susceptibility testing of SQ26,776 against a panel of clinical isolates.
• Comparative analysis of SQ26,776 activity against cephalosporins, penicillins, and aminoglycosides.

Main Results:

• SQ26,776 exhibited significant in vitro activity against most aerobic gram-negative bacilli, including 47 multiresistant strains.
• The compound showed no activity against gram-positive cocci.
• Its activity was comparable to moxalactam, ceftazidime, ceftriaxone, thienamycin, and tobramycin, and superior to mezlocillin.

Conclusions:

• The in vitro profile of SQ26,776 suggests its potential utility in treating infections caused by gram-negative bacilli.
• SQ26,776 represents a promising candidate for further investigation in the fight against multidrug-resistant gram-negative infections.